• Study Resource
  • Explore Categories
    • Arts & Humanities
    • Business
    • Engineering & Technology
    • Foreign Language
    • History
    • Math
    • Science
    • Social Science

    Top subcategories

    • Advanced Math
    • Algebra
    • Basic Math
    • Calculus
    • Geometry
    • Linear Algebra
    • Pre-Algebra
    • Pre-Calculus
    • Statistics And Probability
    • Trigonometry
    • other →

    Top subcategories

    • Astronomy
    • Astrophysics
    • Biology
    • Chemistry
    • Earth Science
    • Environmental Science
    • Health Science
    • Physics
    • other →

    Top subcategories

    • Anthropology
    • Law
    • Political Science
    • Psychology
    • Sociology
    • other →

    Top subcategories

    • Accounting
    • Economics
    • Finance
    • Management
    • other →

    Top subcategories

    • Aerospace Engineering
    • Bioengineering
    • Chemical Engineering
    • Civil Engineering
    • Computer Science
    • Electrical Engineering
    • Industrial Engineering
    • Mechanical Engineering
    • Web Design
    • other →

    Top subcategories

    • Architecture
    • Communications
    • English
    • Gender Studies
    • Music
    • Performing Arts
    • Philosophy
    • Religious Studies
    • Writing
    • other →

    Top subcategories

    • Ancient History
    • European History
    • US History
    • World History
    • other →

    Top subcategories

    • Croatian
    • Czech
    • Finnish
    • Greek
    • Hindi
    • Japanese
    • Korean
    • Persian
    • Swedish
    • Turkish
    • other →
 
Profile Documents Logout
Upload
drug names - Dentalelle Tutoring
drug names - Dentalelle Tutoring

... Therapeutically Equivalent – Equal therapeutic effects during a clinical trial ...
A CROSS-SECTIONAL, OBSERVATIONAL, PROSPECTIVE STUDY FOR EVALUATION OF
A CROSS-SECTIONAL, OBSERVATIONAL, PROSPECTIVE STUDY FOR EVALUATION OF

... contraindications and appropriate dosages to assure a safer use so that we can avoid ADRs [1]. Drugs play an important role in improving human health and promoting well being. However, to produce the desired effect they have to be safe, efficacious and have to be used rationally. In pregnancy, drug ...
Clinical pharmacology - Львівський національний медичний
Clinical pharmacology - Львівський національний медичний

... Pharmacotherapy of patients in this age group is complicated by the presence of several diseases, and therefore the use of various drugs increase the risk of unwanted side reactions (in patients over 60 years - 1.5 times more likely than in youth), changes in pharmacokinetics and pharmacodynamics of ...
What do you know about ECSTASY?
What do you know about ECSTASY?

... • The brain scan on the right belongs to an individual who used Ecstasy many times, but had not used any drugs in the last 3 weeks before the scan. • The bright red spots on the left “normal” brain scan are serotonin ...
What do you know about ECSTASY?
What do you know about ECSTASY?

... • The brain scan on the right belongs to an individual who used Ecstasy many times, but had not used any drugs in the last 3 weeks before the scan. • The bright red spots on the left “normal” brain scan are serotonin ...
File - Doctorswriting
File - Doctorswriting

... 1st generation H1 blockers are nonsedating agents. Promethazine is more potent than procaine as a local anaesthetic. Interaction of some 2nd generation H1 blockers with tomato juice can increase the drug levels leading to torsade de pointes. Cyproheptadine has prominent blocking effects at dopamine ...
A: There are only a small number of drugs that have unique side
A: There are only a small number of drugs that have unique side

... to be “more sensitive to” or “have exaggerated responses to” some medications is the extent of individual differences in enzyme systems and effectiveness in metabolizing (processing) different drugs in the body. Recent scientific studies have shown these differences to be genetically based and some ...
Taking Drugs as Directed - Consumer Health Choices
Taking Drugs as Directed - Consumer Health Choices

... • When will the drug start working and how will I know if it is working? • What are the possible side effects and what should I do if I have one? ...
Antiprotozoal and Antihilmintic Drugs
Antiprotozoal and Antihilmintic Drugs

... Many of antiprotozoal drugs cause serious toxic effects and most of them are not safe I n pregnancy. ...
Drug Development Process
Drug Development Process

... (Careers: Scientists, Management, Finance, Accounting, HR, Quality Assurance/Control, Regulatory, Vet Med) ...
Rohypnol - Addictions Foundation Manitoba
Rohypnol - Addictions Foundation Manitoba

... often can occur together. • Substance use may increase the risk of mental health problems. ...
q-dips: computer-based prediction of known and potential drug
q-dips: computer-based prediction of known and potential drug

... for clinicians. To help improve their management, we have developed an «expert» computer application: Q-DIPS (Quantitative Drug Interactions Prediction System). Q-DIPS gives extensive information, in dynamic tables, on which specific isozymes metabolize a given drug, or may be inhibited or induced b ...
Selected module tests in Pharmacology
Selected module tests in Pharmacology

... 16. The main way of enteral administration of drugs is: A. Oral. B. By injection. C. Rectal. D. Permucоus. 17. Point out the incorrect statement: A. The drug distribution in the organism depends on the way they are applied, their pK and organ perfusion. B. AUC means “area under the curve” time/conce ...
Document
Document

... Surface infections-Rabies, Trachoma, Tetanus, Leprosy. ...
Antihelmintic drugs
Antihelmintic drugs

... 2-less common: protenuria,leucopenia ...
lect13a
lect13a

... b. Phase II -tests the efficacy of the drug against the target disease in 100 to 500 volunteer patients but also refines the dosage range and checks for side effects -usually tested via single blind tests in which the patient is unaware of whether he/she has received the drug or a placebo (an inert ...
CHAPTER 16 Drug Abuse and Autism Basic Lecture Outline with
CHAPTER 16 Drug Abuse and Autism Basic Lecture Outline with

... nationwide rank methamphetamine the No. 1 drug they battle today: in a survey of 500 law-enforcement agencies in 45 states released in July by the National Association of Counties, 58 percent said meth is their biggest drug problem, compared with only 19 percent for cocaine, 17 percent for pot and 3 ...
lecture1-GENERAL PHA..
lecture1-GENERAL PHA..

... - Destruction by pH & enzymes - GIT irritation - Food - Drug interactions -Drug-Drug interactions - First pass effect - Low bioavailability Not suitable for  vomiting & unconscious patient  emergency & bad taste drugs ...
Presentation - Faculty of pain medicine
Presentation - Faculty of pain medicine

... individual biology, social environment, and age or stage of development. ...
Link - thejabberwock
Link - thejabberwock

... Thomas Laughren, director, FDA psychiatry products, 2006 ...
What`s Changing on the Prescription Drug List?
What`s Changing on the Prescription Drug List?

... What’s Changing on the Prescription Drug List? Essential Formularies: Individual, Small Group and with Preventive Copays Every year BlueCross BlueShield of Tennessee reviews the Prescription Drug List (PDL) to determine changes based on a drug’s effectiveness, safety and affordability. While many ch ...
drug 2012 - Dr. Timothy Hain`s Home Page
drug 2012 - Dr. Timothy Hain`s Home Page

... 600 treatments reviewed ranging from spinal fluid drainage to numerous medications. Nearly all had 60% efficacy (natural history) A lot of these medications may be placebo’s ...
Investigator-Initiated, Pharma-Sponsored Clinical Trials in Human
Investigator-Initiated, Pharma-Sponsored Clinical Trials in Human

... Marketed Oncology Products (1/2004) • Single-arm, phase 2 trials using marketed drugs to treat a cancer different from that indicated in the approved labeling and using doses and schedules similar to those in the marketed drug labeling • Phase 1 oncology trials of marketed drugs if such therapy is a ...
Advances in Epilepsy Research - Finding a Cure for Epilepsy and
Advances in Epilepsy Research - Finding a Cure for Epilepsy and

... Why do we do clinical trials? • The American Public looks to its government for assurance that therapies developed to treat diseases are both SAFE and EFFECTIVE • The Food and Drug Administration (FDA) is charged with ensuring that safety and effectiveness are proven before a drug is put on pharmac ...
HRP-306: WORKSHEET - Drugs
HRP-306: WORKSHEET - Drugs

... The purpose of this worksheet is to provide support for IRB staff pre-reviewing research involving drugs. This worksheet is to be used. It does not need to be completed or retained. ...
< 1 ... 125 126 127 128 129 130 131 132 133 ... 161 >

Orphan drug

An orphan drug is a pharmaceutical agent that has been developed specifically to treat a rare medical condition, the condition itself being referred to as an orphan disease.In the US and EU it is easier to gain marketing approval for an orphan drug, and there may be other financial incentives, such as extended exclusivity periods, all intended to encourage the development of drugs which might otherwise lack a sufficient profit motive. The assignment of orphan status to a disease and to any drugs developed to treat it is a matter of public policy in many countries, and has resulted in medical breakthroughs that may not have otherwise been achieved due to the economics of drug research and development.According to Thomson Reuters in their 2012 publication ""The Economic Power of Orphan Drugs"", there has been increased investing in orphan drug Research and Development partly due to the U. S. Orphan Drug Act (ODA) 1983 and similar Acts in other regions of the world and also driven by ""high-profile philanthropic funding."" The period between 2001 to 2011 was the ""most productive period in the history of orphan drug development, in terms of average annual orphan drug designations and orphan drug approvals."" For the same decade the compound annual growth rate (CAGR) of the orphan drugs was an ""impressive 25.8 percent, compared to only 20.1 percent for a matched control group of non-orphan drugs."" By 2012 the market for orphan drugs was worth USD$637 million compared to the USD$638 million matched control group of non-orphan drugs, Thomson Reuters.By 2012, ""the revenue-generating potential of orphan drugs [was] as great as for non-orphan drugs, even though patient populations for rare diseases are significantly smaller. Moreover, we suggest that orphan drugs have greater profitability when considered in the full context of developmental drivers including government financial incentives, smaller clinical trial sizes, shorter clinical trial times and higher rates of regulatory success.""
  • studyres.com © 2025
  • DMCA
  • Privacy
  • Terms
  • Report